| Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. | |
| | |
MedLine Citation:
|
PMID: 16959756 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite the recent introduction of new therapeutic approaches to treat heart failure, mortality from heart failure remains high, and patients still frequently experience progression of contractile dysfunction and ongoing left ventricular enlargement. Therefore, new treatments are needed for heart failure that work independently of mechanisms already targeted. Emerging evidence suggests that the failure of the myocardium in heart failure is affected by alterations in the energy substrate metabolism. In particular, there is now evidence that in the failing heart, shifting metabolism away from a preference for fatty acids toward more carbohydrate oxidation can improve contractile function and slow the progression of pump failure. |
| | |
Authors:
|
Gary D Lopaschuk |
Related Documents
:
|
17602936 - C-reactive protein and heart failure after myocardial infarction in the community. 12571546 - Qualitative analysis of living with heart failure. 17966446 - Heart failure and dilated cardiomyopathy associated with severe longstanding untreated ... 11992136 - The 'wet westermark' sign. 11577836 - Noninvasive prediction of sudden death and sustained ventricular tachycardia after acut... 4009956 - An adult case of arrhythmogenic right ventricular dysplasia. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Seminars in cardiothoracic and vascular anesthesia Volume: 10 ISSN: 1089-2532 ISO Abbreviation: Semin Cardiothorac Vasc Anesth Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-08 Completed Date: 2007-01-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9807630 Medline TA: Semin Cardiothorac Vasc Anesth Country: United States |
Other Details:
|
Languages: eng Pagination: 228-30 Citation Subset: IM |
Affiliation:
|
Cardiovascular Research Group, University of Alberta, Edmonton, Alberta, Canada. gary.lopaschuk@ualberta.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Dichloroacetate / therapeutic use Fatty Acids / metabolism* Glucose / metabolism* Heart Failure / drug therapy, metabolism*, physiopathology Humans Insulin / therapeutic use Myocardium / metabolism Trimetazidine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids; 11061-68-0/Insulin; 13425-80-4/Dichloroacetate; 50-99-7/Glucose; 5011-34-7/Trimetazidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glucose-insulin-potassium techniques in cardiac surgery: historical overview and future perspectives...
Next Document: Free Fatty acids and postischemic myocardial function.